← Back to Screener
Atea Pharmaceuticals, Inc. Common Stock (AVIR)
Price$5.70
Favorite Metrics
Price vs S&P 500 (26W)85.69%
Price vs S&P 500 (4W)-6.33%
Market Capitalization$468.47M
All Metrics
Book Value / Share (Quarterly)$3.53
P/TBV (Annual)0.37x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.69
Price vs S&P 500 (YTD)62.06%
Net Profit Margin (TTM)34.46%
EPS (TTM)$-1.95
10-Day Avg Trading Volume0.35M
EPS Excl Extra (TTM)$-1.95
EPS (Annual)$-2.00
ROI (Annual)-38.28%
Cash / Share (Quarterly)$3.86
ROA (Last FY)-36.15%
EBITD / Share (TTM)$-2.21
ROE (5Y Avg)-13.16%
Operating Margin (TTM)39.41%
Cash Flow / Share (Annual)$-1.69
P/B Ratio1.70x
P/B Ratio (Quarterly)1.01x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)1.06x
ROA (TTM)-42.52%
EV / EBITDA (TTM)12.22x
EPS Incl Extra (Annual)$-2.00
Current Ratio (Annual)7.82x
Quick Ratio (Quarterly)7.59x
3-Month Avg Trading Volume0.49M
52-Week Price Return100.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.97
P/S Ratio (Annual)1.33x
Asset Turnover (Annual)0.45x
52-Week High$6.45
EPS Excl Extra (Annual)$-2.00
26-Week Price Return89.68%
Quick Ratio (Annual)7.59x
13-Week Price Return62.88%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.82x
Enterprise Value$372.759
Asset Turnover (TTM)0.42x
Book Value / Share Growth (5Y)-11.91%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)39.44%
Cash / Share (Annual)$3.86
3-Month Return Std Dev57.33%
Net Income / Employee (TTM)$-3
ROE (Last FY)-38.28%
EPS Basic Excl Extra (Annual)$-2.00
Receivables Turnover (TTM)85.42x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.95
ROI (TTM)-46.34%
P/S Ratio (TTM)1.33x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.69
Price vs S&P 500 (52W)70.17%
Year-to-Date Return64.71%
5-Day Price Return0.68%
EPS Normalized (Annual)$-2.00
ROA (5Y Avg)-12.39%
Net Profit Margin (Annual)34.49%
Month-to-Date Return9.29%
Cash Flow / Share (TTM)$-1.57
EBITD / Share (Annual)$-1.98
Operating Margin (Annual)39.39%
ROI (5Y Avg)-13.16%
EPS Basic Excl Extra (TTM)$-1.95
P/TBV (Quarterly)0.41x
P/B Ratio (Annual)1.01x
Pretax Margin (TTM)39.41%
Book Value / Share (Annual)$3.53
Price vs S&P 500 (13W)62.19%
Beta0.43x
P/FCF (Annual)1.58x
Revenue / Share (TTM)$0.00
ROE (TTM)-46.34%
52-Week Low$2.46
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AVIRAtea Pharmaceuticals, Inc. Common Stock | 1.33x | — | — | — | $5.70 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing antiviral therapies for serious viral infections. The company's lead candidate, bemnifosbuvir, is in development for COVID-19, and a combination of bemnifosbuvir and ruzasvir is being evaluated for Hepatitis C treatment.